Royalty Pharma
RPRX
266 hedge funds and large institutions have $10.7B invested in Royalty Pharma in 2021 Q4 according to their latest regulatory filings, with 63 funds opening new positions, 107 increasing their positions, 66 reducing their positions, and 27 closing their positions.
340% more call options, than puts
Call options by funds: $49.1M | Put options by funds: $11.2M
133% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 27
62% more repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 66
15% more funds holding
Funds holding: 232 → 266 (+34)
11% more capital invested
Capital invested by funds: $9.59B → $10.7B (+$1.1B)
0.31% more ownership
Funds ownership: 62.15% → 62.46% (+0.31%)
0% more funds holding in top 10
Funds holding in top 10: 11 → 11 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$240M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$115M |
| 3 |
MAMU
Marathon Asset Management (UK)
London,
United Kingdom
|
+$87.1M |
| 4 |
BlackRock
New York
|
+$48.7M |
| 5 |
State Street
Boston,
Massachusetts
|
+$48.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Berkshire Hathaway
Omaha,
Nebraska
|
-$175M |
| 2 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
-$143M |
| 3 |
VCG
Vantage Consulting Group
Virginia Beach,
Virginia
|
-$127M |
| 4 |
Amundi
Paris,
France
|
-$46.4M |
| 5 |
Morgan Stanley
New York
|
-$41.7M |
RPRX Hedge Fund Activity: Q4 2021 in Review
266 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q4 2021, worth a combined $10.7B — up 11% from $9.59B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new RPRX positions and 27 closed out — a net gain of 36 holders — while 107 added to existing stakes and 66 trimmed.
The largest buyer was Viking Global Investors, adding an estimated $240M. The largest seller was Berkshire Hathaway, cutting an estimated $175M.
- 266 institutional investors held Royalty Pharma (RPRX) as of Q4 2021, up from 232 in Q3 2021.
- Funds reported $10.7B of Royalty Pharma stock for Q4 2021, up 11% quarter-over-quarter.
- 63 funds opened new Royalty Pharma positions in Q4 2021 and 27 closed out, a net change of +36 holders.
- The largest Royalty Pharma buyer in Q4 2021 was Viking Global Investors, an estimated $240M added.
- The largest Royalty Pharma seller in Q4 2021 was Berkshire Hathaway, an estimated $175M sold.
Based on aggregated 13F filings for Q4 2021.